Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

If the number of recent drug approvals for atopic dermatitis (AD) is overwhelming, the future is unlikely to be any less ...

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By ...

Data from the federal government shows that Mississippi consistently ranks in the top five in the nation for its rates of ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a new study.

Metformin, a common medication used to treat type 2 diabetes, may also help reduce the viral reservoir in people living with ...

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Drug seizures at ports, airports, and mail centres in the Republic of Ireland have more than doubled in 2024 compared to the ...

Civil rights groups refer to the measure as the “War on Drugs 2.0.” “We did that,” said No on Prop 36 ... reporters at the ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...